CS
CVAC

Credit Suisse’s CureVac CVAC Stock Holding History

Credit Suisse’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$393K Sell
129,787
-174,072
-57% -$611K ﹤0.01% 2736
2023
Q4 		$1.28M Sell
303,859
-673
-0.2% -$3.65K ﹤0.01% 2178
2023
Q3 		$2.08M Buy
304,532
+7,781
+3% +$68.7K ﹤0.01% 1811
2023
Q2 		$3.09M Buy
296,751
+50,137
+20% +$448K ﹤0.01% 1647
2023
Q1 		$1.72M Buy
246,614
+47,788
+24% +$417K ﹤0.01% 1971
2022
Q4 		$1.2M Buy
198,826
+33,617
+20% +$248K ﹤0.01% 2220
2022
Q3 		$1.3M Buy
165,209
+54,236
+49% +$632K ﹤0.01% 2136
2022
Q2 		$1.51M Buy
110,973
+56,475
+104% +$934K ﹤0.01% 2098
2022
Q1 		$1.07M Buy
54,498
+14,009
+35% +$280K ﹤0.01% 2501
2021
Q4 		$1.39M Buy
40,489
+10,507
+35% +$423K ﹤0.01% 3062
2021
Q3 		$1.64M Buy
29,982
+10,040
+50% +$605K ﹤0.01% 2963
2021
Q2 		$1.47M Buy
+19,942
New +$1.99M ﹤0.01% 3094

Other funds holding CVAC

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Credit Suisse's CVAC Position: Q1 2024 in Review

Credit Suisse reduced its CureVac (CVAC) stake by 57% in Q1 2024, selling an estimated $611K and leaving 129,787 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Credit Suisse first reported a position in CVAC in Q2 2021 and has held it in 12 quarters since. The position peaked at $3.09M in Q2 2023. 90 funds tracked by Wall St. Rank hold CVAC as of Q1 2024.

  • Credit Suisse held 129,787 shares of CureVac worth $393K as of Q1 2024.
  • Credit Suisse sold 174,072 CureVac shares in Q1 2024, an estimated $611K.
  • CureVac made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2736 holding.
  • Credit Suisse first reported a position in CureVac in Q2 2021 and has held it in 12 quarters since.
  • Credit Suisse's CureVac position peaked at $3.09M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held CureVac as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.